Patient-friendly summary
If you read nothing else
Bottom line
Worth discussing with your provider if you have unexplained muscle pain.
Preliminary evidencePublished
Evidence hierarchy
Study participants
patients with acute myofascial pain syndrome recruited from the hospital emergency department
Words decoded
- MPS
- — Myofascial Pain Syndrome, a common pain disorder.
- biomarkers
- — Substances in the blood that can show the presence of a disease or condition.
- cytokines
- — Small proteins released by cells that have an effect on other cells or the immune system.
- chemokines
- — Chemical signals that attract cells to sites of inflammation.
Full research — for clinicians and curious readers
Study Summary
Background
Myofascial pain syndrome (MPS) is one of the most commonly diagnosed pain disorders, affecting 15% of general medical patients and up to 85% in pain clinics. Despite its high prevalence, MPS is often misdiagnosed because there are no objective diagnostic tests. Previous research has found elevated inflammatory markers within muscle trigger points, but no studies had examined whether these inflammatory changes can be detected in blood samples, which would be much more practical for clinical diagnosis.
What They Did
The researchers recruited 37 patients with acute MPS from hospital emergency departments within 24 hours of symptom onset, along with 21 healthy controls. All participants had blood drawn, and researchers measured 15 different inflammatory markers (cytokines, chemokines) and 3 growth factors. Patients were diagnosed using established clinical criteria by an experienced physiatrist. The team analyzed blood levels of key inflammatory substances including IL-6, TNF-α, IL-12, and various chemokines, as well as growth factors FGF-2, PDGF, and VEGF.
What They Found
Patients with acute MPS showed dramatically elevated levels of inflammatory markers compared to healthy controls - in most cases 30 to 70 times higher. Specifically, cytokines IL-6, TNF-α, and IL-12 were all significantly elevated. Eight out of nine chemokines tested were also elevated, including MCP-1, IL-8, and GM-CSF. Growth factors FGF-2, PDGF, and VEGF were all significantly higher in MPS patients.
Interestingly, anti-inflammatory markers IL-1ra and IL-10 were also elevated, suggesting the body was mounting a counter-response to inflammation. The pattern of correlations between different inflammatory markers was much more complex in MPS patients than in controls.
What This Means
This study provides the first evidence that acute myofascial pain creates a systemic inflammatory response that can be detected in blood tests. The findings suggest that MPS is not just a local muscle problem but involves body-wide inflammation. This could lead to the development of blood tests to help diagnose MPS, which would be especially valuable in emergency departments where physicians may not be trained to identify trigger points through physical examination. The elevated growth factors suggest the body is attempting to repair tissue damage.
These biomarkers might also help predict which patients are at risk of developing chronic pain and could guide treatment decisions.
- Inflammatory Marker Elevation
- 30-70x
- Statistical Significance
- p<0.001
- Inflammatory Markers Tested
- 15
58
n=37
Blood draw within 24h
n=21
Single blood draw
MPS Patients
Blood draw within 24h
Healthy Controls
Single blood draw
Results Comparison
IL-6 Levels (pg/mL)
pg/mLKey Findings
| Finding | Detail | Impact |
|---|---|---|
| Cytokines IL-6, TNF-α, and IL-12 were significantly elevated in MPS patients | All three major inflammatory cytokines showed dramatic increases (30-70x) compared to healthy controls | High |
| Eight of nine chemokines were elevated in MPS patients | Including MCP-1, MDC, eotaxin, GM-CSF, IL-8, and MIP-1b, with only MIP-1a showing no difference | High |
| Growth factors FGF-2, PDGF, and VEGF were all significantly higher | Suggesting tissue repair mechanisms are activated in response to muscle injury | Medium |
| Anti-inflammatory markers also elevated | IL-1ra and IL-10 levels were higher in MPS patients, indicating counter-regulatory response | Medium |
| Complex correlation patterns between markers in MPS | Far more significant correlations between inflammatory markers in MPS patients than controls | Low |
Strengths
- First study to examine systemic biomarkers in acute MPS
- Recruited patients within 24 hours of symptom onset
- Comprehensive panel of 18 different biomarkers tested
- Clear diagnostic criteria applied by experienced physiatrist
Limitations
- Relatively small sample size (37 MPS, 21 controls)
- Single time point measurement - no longitudinal data
- Cannot determine if biomarkers predict chronic pain development
- Did not examine relationship between biomarker levels and pain severity
Key Takeaways for Patients
What This Means for You
Your muscle pain may cause inflammation throughout your whole body, not just where it hurts
Blood tests might someday help doctors diagnose trigger point problems more accurately
The elevated growth factors suggest your body is actively trying to heal the damaged muscle tissue
This research may lead to better treatments targeting the underlying inflammation
Having systemic inflammation explains why myofascial pain can make you feel generally unwell